Researchers discovered that a protein called PR3 plays a major role in damaging kidneys in people with diabetes. Using mouse models, scientists found that when they removed or blocked PR3, the kidneys stayed healthier and didn’t leak as much protein in urine. This protein triggers a process that causes kidney cells (called podocytes) to die. The findings suggest that blocking PR3 could become a new treatment for diabetic kidney disease, one of the most common causes of kidney failure. This research opens a promising new path for protecting kidneys in people with diabetes.
The Quick Take
- What they studied: Whether a protein called PR3 causes kidney damage in diabetes and whether blocking it could protect the kidneys
- Who participated: Laboratory mice with diabetes created through specific procedures, plus mouse kidney cells grown in dishes. No human participants were involved in this study.
- Key finding: When researchers removed or blocked PR3 in diabetic mice, the mice had significantly less kidney damage, less protein leaking into urine, and better-preserved kidney cells compared to mice with normal PR3 levels.
- What it means for you: This research suggests a new potential treatment target for diabetic kidney disease, but it’s still in early stages. Human studies would be needed before any new treatment could be used in patients. If you have diabetes, continue following your doctor’s current treatment plan while researchers work on developing new therapies.
The Research Details
This was a laboratory research study using mice with diabetes and kidney cells grown in dishes. The researchers created diabetic kidney disease in mice using three methods: removing one kidney, injecting a chemical that damages the pancreas, and feeding a high-fat diet. They then studied what happened when they removed the PR3 gene from these mice or blocked the PR3 protein. They also grew mouse kidney cells in high-sugar conditions (mimicking diabetes) to watch how PR3 affected cell death. Finally, they tested a protein called elafin that can block PR3 activity by injecting it directly into mouse kidneys.
The study involved multiple approaches to confirm their findings: genetic removal of PR3, blocking PR3 with a natural inhibitor, and increasing PR3 to see if it made damage worse. This multi-pronged approach strengthens the evidence that PR3 is truly responsible for the kidney damage they observed.
The researchers measured several important outcomes including protein in urine (a sign of kidney damage), changes in kidney structure under a microscope, and whether kidney cells were dying through a process called apoptosis.
This research approach is important because it identifies a specific protein that drives kidney damage in diabetes. Rather than just describing what goes wrong, the scientists pinpointed the exact mechanism and showed that removing or blocking this one protein can prevent damage. This is valuable because it suggests a specific target for new medications.
This study has several strengths: it used multiple different approaches to confirm findings (genetic removal, blocking the protein, and overexpressing it), tested the findings in both whole animals and isolated cells, and examined the specific mechanism of how PR3 causes damage. The main limitation is that all work was done in mice and laboratory cells, not in humans. Mouse studies don’t always translate directly to human medicine, so human studies would be needed to confirm these findings are relevant to people with diabetes.
What the Results Show
When researchers removed the PR3 gene from diabetic mice, these mice had dramatically less kidney damage compared to diabetic mice with normal PR3. Specifically, the PR3-lacking mice had much less protein leaking into their urine (a key sign of kidney damage), less scarring and thickening of kidney tissue, and better preservation of the specialized kidney cells called podocytes that filter blood.
In laboratory dishes, when kidney cells were exposed to high sugar levels (simulating diabetes), PR3 levels increased and became more active. This activated PR3 then triggered a cell death process called apoptosis. When researchers removed PR3 from these cells or blocked it with a protein called elafin, the cells survived much better even in high sugar.
When researchers artificially increased PR3 in kidney cells, it made the cell death process much worse, confirming that more PR3 equals more cell death. This dose-response relationship strengthens the evidence that PR3 is directly causing the damage.
Finally, when researchers injected elafin (a PR3 blocker) directly into the kidneys of diabetic mice, it significantly reduced podocyte loss and other signs of kidney disease, suggesting this could be a viable treatment approach.
The study also tested PR3 blocking in mice with a different type of kidney damage (caused by a drug called adriamycin) and found protection there too, suggesting PR3 may be important in multiple types of kidney disease, not just diabetes-related damage. The researchers identified that PR3 works by activating a specific cell death pathway involving a protein called caspase-3, providing insight into the exact mechanism of damage.
Previous research knew that podocytes (kidney filtering cells) die in diabetic kidney disease, but the specific proteins causing this death weren’t well understood. This study identifies PR3 as a key player in this process. PR3 was previously known mainly for its role in immune cells, so this research expands our understanding of where PR3 acts and what damage it can cause. The findings fit with other recent research showing that inflammatory proteins contribute to diabetic kidney disease.
The major limitation is that all experiments were performed in mice and laboratory cell cultures, not in humans. Mice don’t always respond the same way humans do to treatments. The study doesn’t tell us whether blocking PR3 would be safe or effective in people with diabetes. Additionally, the study doesn’t examine what happens over very long time periods or in different types of diabetes (type 1 vs. type 2). The researchers also didn’t test whether blocking PR3 would work in mice that already had established kidney disease, only in mice being treated from the beginning of disease development.
The Bottom Line
Based on this research alone, there are no new recommendations for people with diabetes. This is early-stage laboratory research. Current standard treatments for diabetic kidney disease (blood sugar control, blood pressure management, and certain medications like ACE inhibitors) remain the evidence-based approach. However, this research suggests that PR3-blocking drugs may become a future treatment option and warrants further investigation in human studies. Confidence level: Low for human application (this is preliminary research).
People with diabetes who are concerned about kidney disease should be aware of this research as a promising future direction, but should not expect new treatments immediately. Kidney disease researchers and pharmaceutical companies developing new treatments should pay attention to PR3 as a potential drug target. Healthcare providers treating diabetic kidney disease should monitor for future developments in this area.
This research is in early stages. Even if PR3-blocking drugs prove safe and effective in humans, it typically takes 5-10 years or more to develop and test new medications before they become available to patients. Don’t expect PR3-blocking treatments to be available soon, but this research suggests they may be worth pursuing.
Want to Apply This Research?
- Users with diabetes should track their urine protein levels (if their doctor orders urinalysis tests) and kidney function tests (creatinine and eGFR) every 3-6 months. Record these values in the app to monitor kidney health trends over time and share with healthcare providers.
- While waiting for potential new treatments, users should focus on proven kidney-protective behaviors: maintaining target blood sugar levels, keeping blood pressure controlled, taking prescribed kidney-protective medications, staying hydrated, and following a kidney-friendly diet. The app can help track these daily actions.
- Set up quarterly reminders to review kidney function test results with your doctor. Track blood pressure daily and blood sugar as recommended by your healthcare provider. Monitor for signs of worsening kidney function (increased swelling, fatigue, or changes in urination) and report these to your doctor promptly. Use the app to maintain a health timeline showing kidney function trends over months and years.
This research was conducted in mice and laboratory cells, not in humans. The findings are preliminary and do not yet represent a treatment available for people with diabetes. If you have diabetes or kidney disease, continue following your doctor’s current treatment recommendations. Do not stop or change any medications based on this research. Speak with your healthcare provider about your individual kidney health and risk factors. This article is for educational purposes only and should not be considered medical advice. Future human studies would be needed to determine whether PR3-blocking treatments are safe and effective in people.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.